Performance analysis of X.T.L. Biopharmaceuticals (XTLB)
Annual Return
Over the past 3 years, XTLB has had an average annual return of -23.15%, underperforming the benchmark SPY, which returned +22.77% annual.
Over the past 5 years, XTLB has had an average annual return of -30.59%, underperforming the benchmark SPY, which returned +14% annual.
Over the past 10 years, XTLB has had an average annual return of -20.08%, underperforming the benchmark SPY, which returned +15.53% annual.
Since Sep 1, 2005, XTLB has had an average annual return of -28.30%, underperforming the benchmark SPY, which returned +11.22% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +0% | -71.43% | +94.44% | -14.29% | -57.14% | -7.55% | +120.83% | -20.00% | -25.00% | -28.57% | -54.47% | -28.90% |
| 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | ||
| -31.89% | -60.92% | +95.20% | -19.17% | +368.18% | +100% | -98.24% | +4.04% | -64.61% | -32.22% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +50% | -13.33% | -15.38% | +54.55% | -35.29% | -9.09% | +0% | ||||||
| 2025 | -20.00% | -21.43% | -4.55% | +19.05% | -16.00% | -4.76% | +25% | -12.00% | -9.09% | -5.00% | -21.05% | -33.33% | -71.43% |
| 2024 | -16.67% | +0% | +226.67% | -8.16% | +2.22% | -6.52% | +18.60% | -3.92% | -14.29% | -7.14% | -15.38% | +6.06% | +94.44% |
| 2023 | -4.76% | +25% | -8.00% | -13.04% | +10% | -18.18% | -22.22% | +28.57% | -11.11% | -6.25% | +20% | +0% | -14.29% |
| 2022 | -10.20% | -4.55% | -0% | -7.14% | -17.95% | -15.63% | +7.41% | -10.34% | -26.92% | +21.05% | +0% | -8.70% | -57.14% |
| 2021 | +1.89% | +3.70% | +3.57% | +12.07% | -4.62% | +12.90% | -12.86% | +42.62% | -11.49% | -12.99% | -16.42% | -12.50% | -7.55% |
| 2020 | +20.83% | -20.69% | -8.70% | -0% | +9.52% | +21.74% | -0% | +7.14% | +10% | +12.12% | +16.22% | +23.26% | +120.83% |
| 2019 | +43.33% | -6.98% | +2.50% | +0% | -14.63% | +0% | -2.86% | -2.94% | -24.24% | -4.00% | -4.17% | +4.35% | -20.00% |
| 2018 | -2.50% | -20.51% | -3.23% | -10.00% | +22.22% | +0% | -6.06% | +3.23% | +21.87% | +12.82% | -2.27% | -30.23% | -25.00% |
| 2017 | +1.79% | -38.60% | +31.43% | +2.17% | -2.13% | +19.57% | +9.09% | -21.67% | -10.64% | -4.76% | +5% | -4.76% | -28.57% |
Drawdown analysis of X.T.L. Biopharmaceuticals (XTLB)
The maximum drawdown for the XTLB was -99.90%, occurring on Dec 31, 2025. This drawdown has not yet recovered.
The current XTLB drawdown is -99.90%.
Since Sep 1, 2005 XTLB has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 1 time
- 10% or more: 1 time
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.90% | Sep 1, 2005 | 5114 | Dec 31, 2025 | Ongoing | Ongoing | Ongoing |